See the DrugPatentWatch profile for tigecycline

The maximum safe dosage of Tigecycline, an antibiotic used to treat various bacterial infections, is a complex question as it can depend on several factors including the patient's weight, kidney function, liver function, and the type and severity of the infection.

However, according to the drug's prescribing information, the recommended dosage for adults is an initial dose of 100 mg, followed by 50 mg every 12 hours [1]. This dosage is the same regardless of the patient's weight. The maximum daily dosage is 200 mg.

In special populations, the dosage may need to be adjusted. For instance, in patients with severe kidney impairment, the dosing interval should be extended to every 24 hours [1].

It's important to note that Tigecycline has a boxed warning, the most serious type of warning issued by the FDA, for increased mortality in patients treated for certain types of infections [1]. Therefore, it's crucial that the drug is used appropriately and under the supervision of a healthcare professional.

As for the safety of Tigecycline, a study published in the Journal of Antimicrobial Chemotherapy found that the drug was well-tolerated at the recommended dosage [2]. The most common adverse events were nausea and vomiting.

In terms of patent information, according to DrugPatentWatch.com, the patent for Tigecycline expired in 2018 [3]. This means that generic versions of the drug are now available on the market, which could increase accessibility and affordability of the drug.

In conclusion, the maximum safe dosage of Tigecycline is generally 200 mg per day, but it can vary depending on the patient's condition and kidney function. The drug has a boxed warning for increased mortality in certain types of infections, and it's important that it's used appropriately under medical supervision.

Sources:
[1] Wyeth Pharmaceuticals Inc., Tigecycline package insert, 2017.
[2] H. F. Giamarellou et al., "Tigecycline in the treatment of complicated skin and soft tissue infections and complicated intra-abdominal infections: a randomized, double-blind, multicenter phase III study," Journal of Antimicrobial Chemotherapy, vol. 59, no. 5, pp. 963-973, 2007.
[3] "Tigecycline (Tygacil) Drug Profile," DrugPatentWatch.com, 2022. [Online]. Available: https://www.drugpatentwatch.com/drugs/tigecycline.aspx.